Back to News
Press Release November 15, 2017

NEWS & EVENTS

News Image

Paris, November 15, 2017.Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, today announced that the European Medicines Agency (EMA) has granted access to its PRIority MEdicines (PRIME) scheme for its lead product MOTREMTM in the field of septic shock.

Read full article – PDF


Read full article